The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Open accessAbstract
Amplification of and oncogenic mutations in ERBB2, the gene encoding the HER2 receptor tyrosine kinase, promote receptor hyperactivation and tumor growth. Here we demonstrate that HER2 ubiquitination and internalization, rather than its overexpression, are key mechanisms underlying endocytosis and consequent efficacy of the anti-HER2 antibody–drug conjugates (ADC) ado-trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) in lung cancer cell lines and patient-derived xenograft models. These data translated into a 51% response rate in a clinical trial of T-DM1 in 49 patients with ERBB2-amplified or -mutant lung cancers. We show that cotreatment with irreversible pan-HER inhibitors enhances receptor ubiquitination and consequent ADC internalization and efficacy. We also demonstrate that ADC switching to T-DXd, which harbors a different cytotoxic payload, achieves durable responses in a patient with lung cancer and corresponding xenograft model developing resistance to T-DM1. Our findings may help guide future clinical trials and expand the field of ADC as cancer therapy. Significance: T-DM1 is clinically effective in lung cancers with amplification of or mutations in ERBB2. This activity is enhanced by cotreatment with irreversible pan-HER inhibitors, or ADC switching to T-DXd. These results may help address unmet needs of patients with HER2-activated tumors and no approved targeted therapy. See related commentary by Rolfo and Russo, p. 643. This article is highlighted in the In This Issue feature, p. 627
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Self-citationTucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914609 · Cited by 1,326
Self-citationShen, R., & Seshan, V. E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw520 · Cited by 1,258
Self-citationOgitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
Microtubules and resistance to tubulin-binding agents
Kavallaris, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2803 · Cited by 1,120
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780
Self-citationJordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1337 · Cited by 643
Self-citationChan, A., Delaloge, S., Holmes, F. A., Moy, B., Iwata, H., Harvey, V. J., Robert, N. J., Silovski, T., Gokmen, E., von Minckwitz, G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00551-3 · Cited by 561
Li, B. T., Shen, R., Buonocore, D., Olah, Z. T., Ni, A., Ginsberg, M. S., Ulaner, G. A., Offin, M., Feldman, D., Hembrough, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9777 · Cited by 556
Self-citationBanerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30328-6 · Cited by 547
Mimnaugh, E. G., Chavany, C., & Neckers, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22796 · Cited by 466
Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. L., Pedersen, K., Smith, D. J., Landolfi, S., Ramon y Cajal, S., Arribas, J., et al. (2009) · Oncogene · doi:10.1038/onc.2008.432 · Cited by 439
Self-citationChaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu
Xu, W., Marcu, M., Yuan, X., Mimnaugh, E., Patterson, C., & Neckers, L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202365899 · Cited by 433
Gatzemeier, U., Groth, G., Butts, C., Van Zandwijk, N., Shepherd, F., Ardizzoni, A., Barton, C., Ghahramani, P., & Hirsh, V. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh031 · Cited by 388
Tamura, K., Tsurutani, J., Takahashi, S., Iwata, H., Krop, I. E., Redfern, C., Sagara, Y., Doi, T., Park, H., Murthy, R. K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30097-x · Cited by 352
Self-citationKris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv186 · Cited by 334 · cited 1×
“We also observed clinical activity of T-DM1 across all activating HER2 mutation subtypes (Supplementary Table S1), in contrast to the differential activity of tyrosine kinase inhibitors across mutation subtypes seen in previous studies (11, 30, 31).”
ResultSelf-citationCoats, S., Williams, M., Kebble, B., Dixit, R., Tseng, L., Yao, N.-S., Tice, D. A., & Soria, J.-C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0272 · Cited by 289
Robichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., Zhang, F., Pisegna, M., Poteete, A., Sun, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.001 · Cited by 242
Peters, S., Stahel, R., Bubendorf, L., Bonomi, P., Villegas, A., Kowalski, D. M., Baik, C. S., Isla, D., Carpeno, J. D. C., Garrido, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1590 · Cited by 236
Citri, A. (2002) · The EMBO Journal · doi:10.1093/emboj/21.10.2407 · Cited by 233
Shitara, K., Iwata, H., Takahashi, S., Tamura, K., Park, H., Modi, S., Tsurutani, J., Kadowaki, S., Yamaguchi, K., Iwasa, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30088-9 · Cited by 232
Self-citationWang, Y., Jiang, T., Qin, Z., Jiang, J., Wang, Q., Yang, S., Rivard, C., Gao, G., Ng, T. L., Tu, M. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy542 · Cited by 207
Self-citationEndocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies
Chew, H. Y., De Lima, P. O., Gonzalez Cruz, J. L., Banushi, B., Echejoh, G., Hu, L., Joseph, S. R., Lum, B., Rae, J., O’Donnell, J. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.019 · Cited by 186
A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer
Hotta, K., Aoe, K., Kozuki, T., Ohashi, K., Ninomiya, K., Ichihara, E., Kubo, T., Ninomiya, T., Chikamori, K., Harada, D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.032 · Cited by 179
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
Nakada, T., Masuda, T., Naito, H., Yoshida, M., Ashida, S., Morita, K., Miyazaki, H., Kasuya, Y., Ogitani, Y., Yamaguchi, J., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.020 · Cited by 172
Dziadziuszko, R., Smit, E. F., Dafni, U., Wolf, J., Wasąg, B., Biernat, W., Finn, S. P., Kammler, R., Tsourti, Z., Rabaglio, M., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.017 · Cited by 160
VanderWeele, D. J., Zhou, R., & Rudin, C. M. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1605.3.12 · Cited by 116
Self-citationHerbst, R. S., Davies, A. M., Natale, R. B., Dang, T. P., Schiller, J. H., Garland, L. L., Miller, V. A., Mendelson, D. S., den Abbeele, A. D. V., Melenevsky, Y. V., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0460 · Cited by 102
Frequency and outcomes of brain metastases in patients with HER2‐mutant lung cancers
Offin, M. D., Feldman, D., Ni, A., Myers, M. L., Lai, W. V., Pentsova, E. I., Boire, A. A., Daras, M., Jordan, E., Solit, D. B., et al. (2019) · Cancer · doi:10.1002/cncr.32461 · Cited by 100
Self-citationPrevalence and role of HER2 mutations in cancer
Cocco, E., Lopez, S., Santin, A. D., & Scaltriti, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.010 · Cited by 92
Self-citationPeters, S., Fontecedro, A. C., Nechushtan, H., Shih, J., Liao, W., Gautschi, O. P., Spataro, V. J., Unk, M., Yang, J. C., Lorence, R. M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.093 · Cited by 90
Self-citationZhang, Y., Zhang, J., Liu, C., Du, S., Lü, F., Luan, X., Zhang, Y., Shi, Y., Wang, T., Wu, Y., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.08.026 · Cited by 88
Lai, W. V., Lebas, L., Barnes, T. A., Milia, J., Ni, A., Gautschi, O. P., Peters, S., Ferrara, R., Plodkowski, A. J., Kavanagh, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.030 · Cited by 82
Self-citationAbraham, J., Montero, A. J., Jankowitz, R. C., Salkeni, M. A., Beumer, J. H., Kiesel, B. F., Piette, F., Adamson, L. M., Nagy, R. J., Lanman, R. B., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00858 · Cited by 80
NSCLC and HER2: between lights and shadows
Ricciardi, G. R. R., Russo, A., Franchina, T., Ferraro, G., Zanghì, M., Picone, A., Scimone, A., & Adamo, V. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000379 · Cited by 78
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
Cocco, E., Carmona, F. J., Razavi, P., Won, H. H., Cai, Y., Rossi, V., Chan, C., Cownie, J., Soong, J., Toska, E., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aat9773 · Cited by 74
Self-citationNovel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
Baraibar, I., Mezquita, L., Bazo, I. G., & Planchard, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102906 · Cited by 72
Biomarkers of drugs targeting HER ‐family signalling in cancer
Montemurro, F., & Scaltriti, M. (2013) · The Journal of Pathology · doi:10.1002/path.4269 · Cited by 60
Self-citationUlaner, G. A., Saura, C., Piha-Paul, S. A., Mayer, I. A., Quinn, D. I., Jhaveri, K. L., Stone, B., Shahin, S., Mann, G., Dujka, M. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1658 · Cited by 21
Self-citation
Cited by
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L., Saltos, A. N., Felip, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,021
Self-citationOvercoming therapy resistance in EGFR-mutant lung cancer
Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565
Imyanitov, E. N., Iyevleva, A. G., & Levchenko, E. V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103194 · Cited by 526
Metadata
- Authors
- Li, B. T., Michelini, F., Misale, S., Cocco, E., Baldino, L., Cai, Y., Shifman, S., Tu, H.-Y., Myers, M. L., Xu, C., Mattar, M., Khodos, I., Little, M., Qeriqi, B., Weitsman, G., Wilhem, C. J., Lalani, A. S., Diala, I., Freedman, R. A., Lin, N. U., Solit, D. B., Berger, M. F., Barber, P. R., Ng, T., Offin, M., Isbell, J. M., Jones, D. R., Yu, H. A., Thyparambil, S., Liao, W.-L., Bhalkikar, A., Cecchi, F., Hyman, D. M., Lewis, J. S., Buonocore, D. J., Ho, A. L., Makker, V., Reis-Filho, J. S., Razavi, P., Arcila, M. E., Kris, M. G., Poirier, J. T., Shen, R., Tsurutani, J., Ulaner, G. A., de Stanchina, E., Rosen, N., Rudin, C. M., & Scaltriti, M.
- Venue
- Cancer Discovery
- Published
- 2020-05-01
- Volume
- 10
- Issue
- 5
- Pages
- 674-687
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3013150216
- Cited by
- 288
- References
- 43
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.